|
1
|
Matsuno S, Egawa S, Fukuyama S, Motoi F,
Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, et al:
Pancreatic cancer registry in Japan: 20 years of experience.
Pancreas. 28:219–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Imamura M, Doi R, Imaizumi T, Funakoshi A,
Wakasugi H, Sunamura M, Ogata Y, Hishinuma S, Asano T, Aikou T, et
al: A randomized multicenter trial comparing resection and
radiochemotherapy for resectable locally invasive pancreatic
cancer. Surgery. 136:1003–1011. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bilimoria KY, Talamonti MS, Sener SF,
Bilimoria MM, Stewart AK, Winchester DP, Ko CY and Bentrem DJ:
Effect of hospital volume on margin status after
pancreaticoduodenectomy for cancer. J Am Coll Surg. 207:510–519.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klautke G and Brunner TB: Radiotherapy in
pancreatic cancer. Strahlenther Onkol. 184:557–564. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ueno H, Ioka T, Ikeda M, Ohkawa S,
Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et
al: Randomized phase III study of gemcitabine plus S-1, S-1 alone,
or gemcitabine alone in patients with locally advanced and
metastatic pancreatic cancer in Japan and Taiwan: GEST study. J
Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Motoi F, Ishida K, Fujishima F, Ottomo S,
Oikawa M, Okada T, Shimamura H, Takemura S, Ono F, Akada M, et al:
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable
and borderline pancreatic ductal adenocarcinoma: Results from a
prospective multi-institutional phase 2 trial. Ann Surg Oncol.
20:3794–3801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moertel CG, Frytak S, Hahn RG, O'Connell
MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS,
Holbrook MA, et al: Therapy of locally unresectable pancreatic
carcinoma: A randomized comparison of high dose (6000 rads)
radiation alone, moderate dose radiation (4000 rads+5-fluorouracil)
and high dose radiation+5-fluorouracil: The gastrointestinal tumor
study group. Cancer. 48:1705–1710. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loehrer PJ Sr, Feng Y, Cardenes H, Wagner
L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR
and Benson AB III: Gemcitabine alone versus gemcitabine plus
radiotherapy in patients with locally advanced pancreatic cancer:
An Eastern Cooperative Oncology Group trial. J Clin Oncol.
29:4105–4112. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pisters PW, Hudec WA, Lee JE, Raijman I,
Lahoti S, Janjan NA, Rich TA, Crane CH, Lenzi R, Wolff RA, et al:
Preoperative chemoradiation for patients with pancreatic cancer:
Toxicity of endobiliary stents. J Clin Oncol. 18:860–867.
2000.PubMed/NCBI
|
|
11
|
Krishnan S, Rana V, Janjan NA,
Varadhachary GR, Abbruzzese JL, Das P, Delclos ME, Gould MS, Evans
DB and Wolff RA: Induction chemotherapy selects patients with
locally advanced, unresectable pancreatic cancer for optimal
benefit from consolidative chemoradiation therapy. Cancer.
110:47–55. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yovino S, Poppe M, Jabbour S, David V,
Garofalo M, Pandya N, Alexander R, Hanna N and Regine WF:
Intensity-modulated radiation therapy significantly improves acute
gastrointestinal toxicity in pancreatic and ampullary cancers. Int
J Radiat Oncol Biol Phys. 79:158–162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ben-Josef E, Shields AF, Vaishampayan U,
Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J,
Bossenberger T and Philip PA: Intensity-modulated radiotherapy
(IMRT) and concurrent capecitabine for pancreatic cancer. Int J
Radiat Oncol Biol Phys. 59:454–459. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murphy JD, Adusumilli S, Griffith KA, Ray
ME, Zalupski MM, Lawrence TS and Ben-Josef E: Full-dose gemcitabine
and concurrent radiotherapy for unresectable pancreatic cancer. Int
J Radiat Oncol Biol Phys. 68:801–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura A, Shibuya K, Matsuo Y, Nakamura
M, Shiiinoki T, Mizowaki T and Hiraoka M: Analysis of dosimetric
parameters associated with acute gastrointestinal toxicity and
upper gastrointestinal bleeding in locally advanced pancreatic
cancer patients treated with gemcitabine-based concurrent
chemoradiotherapy. Int J Radiat Oncol Biol Phys. 84:369–375. 2012.
View Article : Google Scholar : PubMed/NCBI
|
